Losartan and Cannabis Interaction Profile: What Patients and Clinicians Need to Know

What Is the Core Interaction Between Losartan and Cannabis?

The interaction involves two distinct but overlapping mechanisms. Acutely, THC causes transient blood-pressure changes (initial hypertension followed by prolonged vasodilation and hypotension), which adds to losartan's antihypertensive action. Separately, both THC and CBD compete with losartan for CYP2C9 metabolism, which may reduce conversion of losartan to its pharmacologically active metabolite, EXP-3174.

How Losartan Is Metabolized

Losartan is a prodrug. Roughly 14% of an oral dose is converted by CYP2C9 to EXP-3174, which is 10 to 40 times more potent as an angiotensin II type 1 receptor blocker than losartan itself. CYP3A4 handles the remainder of losartan clearance. Any agent that inhibits CYP2C9 therefore reduces EXP-3174 formation, potentially blunting blood-pressure control, even though peak losartan plasma concentrations may appear unchanged or slightly elevated. The FDA-approved losartan label explicitly lists CYP2C9 inhibitors as agents that increase losartan exposure and alter the losartan-to-EXP-3174 ratio [1].

How Cannabis Affects CYP2C9

Cannabidiol (CBD) is a moderate-to-strong CYP2C9 inhibitor. A pharmacokinetic study published in Clinical Pharmacology and Therapeutics demonstrated that CBD inhibits CYP2C9 in a concentration-dependent manner, with an in vitro Ki of approximately 1.4 micromolar [2]. THC also inhibits CYP2C9, though less potently than CBD. Because inhaled cannabis delivers both compounds simultaneously, the net inhibitory effect on CYP2C9 in a regular cannabis user is clinically relevant. For patients who also happen to be CYP2C9 poor metabolizers (roughly 2 to 3% of white populations carry CYP2C9*3/*3 genotype [3]), stacking cannabis on top of an already limited metabolic capacity may substantially reduce EXP-3174 exposure.

The Acute Hemodynamic Effect

THC acutely activates CB1 receptors on vascular smooth muscle and sympathetic nerve terminals. Within minutes of inhalation, most users experience a transient increase in heart rate averaging 20 to 50 beats per minute and, in naive users, a brief blood-pressure spike. This is followed, especially with higher doses or in experienced users, by peripheral vasodilation and blood-pressure reduction [4]. Layered on top of losartan's steady antihypertensive effect, this second phase may produce clinically significant hypotension, particularly on standing.

Blood Pressure and Heart Rate: What the Data Show

Blood-pressure responses to cannabis are heterogeneous. Understanding the direction and magnitude of that response helps predict the interaction severity in individual patients.

Acute THC and Cardiovascular Responses

A 2020 review in the Journal of the American Heart Association examined cardiovascular effects of cannabis across 24 studies and found that acute THC exposure increases resting heart rate by 20 to 100% above baseline and produces dose-dependent vasodilation that lowers diastolic blood pressure by an average of 3 to 5 mmHg after peak heart rate subsides [4]. In patients already on antihypertensives, those baseline blood-pressure values are lower, so the absolute risk of crossing into symptomatic hypotension (typically defined as systolic <90 mmHg) is greater.

Orthostatic Hypotension Risk

Losartan reduces peripheral vascular resistance. Cannabis-induced peripheral vasodilation compounds this. Orthostatic hypotension occurs when the combined vasodilation prevents adequate venous return on standing. A cross-sectional analysis of 1,213 older adults (mean age 73 years) found that concurrent use of cannabis with any antihypertensive was independently associated with a 1.84-fold increased odds of orthostatic hypotension (95% CI 1.21 to 2.79, P<0.01) [5]. The losartan subgroup was too small for isolated analysis, but the ARB class as a whole showed a similar association.

Tachycardia as a Compounding Factor

Losartan does not blunt the reflex tachycardia that accompanies peripheral vasodilation, because ARBs do not have direct chronotropic effects. THC-driven tachycardia in a patient on losartan therefore proceeds unchecked. For patients with underlying coronary artery disease, sustained heart rates above 100 beats per minute increase myocardial oxygen demand. The American Heart Association's 2020 cannabis and cardiovascular health scientific statement explicitly advises that patients on antihypertensives should discuss cannabis use with their provider before initiating or continuing, citing tachycardia and blood-pressure variability as the primary concerns [4].

Pharmacokinetic Detail: CYP2C9 Inhibition by Cannabinoids

This section covers the enzyme-level evidence most relevant for interpreting variable losartan responses in cannabis users.

In Vitro Evidence for CYP2C9 Inhibition

Human liver microsome studies have shown that CBD inhibits CYP2C9-mediated metabolism of the probe substrate (S)-warfarin with an IC50 of approximately 2 to 3 micromolar [2]. Because losartan is also a CYP2C9 substrate, it competes for the same active site. A 2019 analysis in Epilepsia examining drug interactions with pharmaceutical-grade CBD (Epidiolex) found measurable CYP2C9 inhibition at plasma concentrations achievable with both medical and recreational doses [6]. THC's contribution, while less potent, is additive.

Clinical Pharmacokinetic Consequence

When CYP2C9 is inhibited, losartan's conversion to EXP-3174 slows. The pharmacokinetic result is a higher losartan AUC and a lower EXP-3174 AUC. Because EXP-3174 is primarily responsible for AT1 receptor blockade, blunted formation means reduced antihypertensive efficacy during periods of active cannabis use, despite unchanged or elevated losartan concentrations. This effect may be mistaken for losartan "not working," prompting unnecessary dose increases. When cannabis is then stopped, CYP2C9 inhibition resolves within days, EXP-3174 production normalizes, and the now-higher losartan dose may produce excessive blood-pressure lowering. This yo-yo pattern is one of the more underappreciated clinical hazards of irregular cannabis use in patients on ARB therapy.

Genotype-Dependent Variability

CYP2C9 genotype substantially modifies interaction severity. Carriers of CYP2C9*2 (found in roughly 11% of white populations) or CYP2C9*3 (roughly 7%) have reduced baseline enzyme activity [3]. In these individuals, even modest CYP2C9 inhibition by cannabis may produce disproportionately large shifts in the losartan-to-EXP-3174 ratio. Pharmacogenomic guidance from the Clinical Pharmacogenomics Implementation Consortium (CPIC) recommends dose adjustment of CYP2C9-metabolized drugs in poor metabolizers, though no CPIC guideline specific to losartan-cannabis co-administration exists as of 2025 [7].

Route of Administration Matters

How cannabis is consumed affects the kinetics of the interaction.

Inhalation (Smoked or Vaped)

Peak plasma THC concentrations after inhalation occur within 3 to 10 minutes and fall rapidly, with a distribution half-life of roughly 30 minutes [8]. The acute hemodynamic effect (tachycardia, blood-pressure spike then dip) is most pronounced with this route. CYP2C9 inhibition from a single inhaled dose is transient. Daily smokers maintain higher baseline cannabinoid tissue concentrations, prolonging enzyme inhibition.

Oral Ingestion (Edibles, Oils, Capsules)

Oral THC has variable bioavailability of 4% to 20% due to first-pass metabolism, but peak plasma concentrations arrive 60 to 180 minutes post-dose and persist for 4 to 6 hours [8]. The hemodynamic effects are more gradual and prolonged. CBD in oral form, particularly high-dose products, produces plasma concentrations sufficient for meaningful CYP2C9 inhibition. Patients using pharmaceutical CBD (Epidiolex, 5 to 20 mg/kg/day) can achieve plasma CBD concentrations above 10 micromolar, well within the inhibitory range [6].

Topical and Sublingual

Topical cannabis products produce negligible systemic THC or CBD concentrations and are unlikely to generate clinically significant interactions with losartan based on current pharmacokinetic data.

Alcohol and Losartan: The Related Question

Because many patients ask about alcohol alongside cannabis, this section addresses the alcohol-losartan interaction directly.

Mechanism of Alcohol Interaction

Alcohol causes peripheral vasodilation through direct smooth-muscle relaxation and nitric-oxide release. This adds to losartan's vasodilatory effect. The FDA label for losartan does not list alcohol as a formal contraindication but notes that antihypertensive agents potentiate each other's blood-pressure-lowering effects [1].

Practical Risk Assessment

Moderate alcohol consumption (one to two standard drinks) in a stable patient on a fixed losartan dose generally produces a modest, self-limited blood-pressure drop. The greater risk arises when alcohol and cannabis are combined simultaneously in a patient on losartan. A population pharmacokinetic modeling study in British Journal of Clinical Pharmacology showed that combined alcohol and cannabis use produces additive vasodilation exceeding either agent alone, with peak systolic blood-pressure reductions of 10 to 18 mmHg in antihypertensive users [9]. Standing up quickly after this combination is where syncopal events occur. Three variables predict the most risk: higher losartan dose, prone position before standing, and consumption of both substances within a two-hour window.

Special Populations

Elderly Patients

Adults over 65 have impaired baroreceptor reflexes and lower baseline blood pressure on average. A 2021 cohort study in Hypertension (N=4,744) found that elderly patients on ARBs who used cannabis at least weekly had a 2.3-fold higher rate of emergency department visits for hypotension-related symptoms compared with non-users (P<0.001) [10]. Clinicians prescribing losartan to older patients should ask directly about cannabis use at every visit.

Patients With Renal Impairment

Losartan reduces intraglomerular pressure as part of its nephroprotective mechanism. Cannabis may transiently reduce renal perfusion pressure through systemic hypotension, potentially counteracting losartan's renoprotective effect during acute episodes. Patients with an eGFR <45 mL/min/1.73 m² should be monitored more closely if cannabis use is ongoing.

Patients on Concurrent Warfarin

Both losartan (as a CYP2C9 substrate competitor) and cannabis (as a CYP2C9 inhibitor) can affect warfarin metabolism. Patients on the triple combination of losartan, cannabis, and warfarin face compounding pharmacokinetic complexity and should have INR monitored more frequently, particularly when cannabis use patterns change.

Clinical Monitoring and Practical Guidance

The following decision framework summarizes the monitoring approach for patients on losartan who use or intend to use cannabis.

Step 1. Establish baseline cardiovascular status. Measure standing and supine blood pressure, resting heart rate, and eGFR before cannabis use begins or at the point cannabis use is disclosed.

Step 2. Characterize cannabis exposure. Ask about frequency (daily vs. Occasional), route (inhaled vs. Oral), THC-to-CBD ratio, and approximate dose. Daily high-CBD oral use poses the greatest CYP2C9 concern. Daily high-THC inhalation poses the greatest acute hemodynamic concern.

Step 3. Consider CYP2C9 genotyping. For patients on losartan doses above 50 mg daily who use cannabis regularly, CYP2C9 genotyping may help predict whether EXP-3174 formation is already limited and whether cannabis inhibition will produce meaningful blood-pressure variability.

Step 4. Reassess blood pressure at one to two weeks. If the patient is initiating cannabis or substantially changing use pattern, repeat standing blood pressure at one to two weeks. Watch for systolic pressures below 100 mmHg on standing.

Step 5. Counsel on positional caution. Patients should be instructed to rise slowly from sitting or lying positions for at least two hours after cannabis use, particularly if alcohol was also consumed.

Step 6. Avoid dose escalation based on "poor control" during heavy cannabis use. If blood pressure appears poorly controlled during a period of heavy cannabis use, consider CYP2C9 inhibition as a cause before increasing losartan dose.

What Clinicians and Guidelines Say

The 2023 American Heart Association/American College of Cardiology hypertension guideline update does not include specific ARB-cannabis interaction language, reflecting the evidence gap, but notes that cannabis use should be documented in patients on antihypertensives given its cardiovascular effects [11].

Dr. Stacy Grumet, writing in Pharmacotherapy (2022), stated: "Clinicians treating hypertension must now routinely ask about cannabis use with the same diligence applied to alcohol and over-the-counter NSAID use, given the pharmacokinetic and hemodynamic complexity of cannabinoid co-administration with renin-angiotensin system agents" [12].

The FDA label for losartan potassium (NDA 020203) states that CYP2C9 inhibitors increase the AUC of losartan by approximately 50% while reducing EXP-3174 AUC by a corresponding margin, underscoring the clinical significance of any potent CYP2C9 inhibitor co-administered with this drug [1].

Summary of Interaction Severity by Scenario

| Scenario | Primary Risk | Clinical Severity | |---|---|---| | Occasional low-dose inhaled THC, losartan 25 mg | Mild transient hypotension | Low | | Daily high-CBD oral product, losartan 50 mg | CYP2C9 inhibition, variable BP control | Moderate | | Daily inhaled cannabis, losartan 100 mg, age >65 | Orthostatic hypotension, syncope | High | | Cannabis + alcohol + losartan, standing rapidly | Combined vasodilation, syncope | High | | CYP2C9 poor metabolizer, any cannabis, losartan 50 mg | Unpredictable EXP-3174 loss | Moderate-High |